These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 20039407

  • 1. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
    Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP.
    Arthritis Rheum; 2010 Jan; 62(1):150-8. PubMed ID: 20039407
    [Abstract] [Full Text] [Related]

  • 2. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jan; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 3. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 4. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 5. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    Scand J Rheumatol; 2009 Oct; 38(6):439-44. PubMed ID: 19922018
    [Abstract] [Full Text] [Related]

  • 6. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
    Voorzanger-Rousselot N, Journe F, Doriath V, Body JJ, Garnero P.
    Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
    [Abstract] [Full Text] [Related]

  • 7. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 8. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 9. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 19; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 10. Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis.
    Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, Bansal S, Ebringer A.
    J Rheumatol; 1997 Jan 19; 24(1):109-14. PubMed ID: 9002020
    [Abstract] [Full Text] [Related]

  • 11. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
    Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Siedlar M, Grodzicki T.
    Scand J Rheumatol; 2014 Jan 19; 43(1):43-8. PubMed ID: 24447112
    [Abstract] [Full Text] [Related]

  • 12. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N.
    Arthritis Rheum; 2003 Jun 19; 48(6):1521-9. PubMed ID: 12794819
    [Abstract] [Full Text] [Related]

  • 13. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May 19; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 14. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 19; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 15. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May 19; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 16. The potential use of antibacterial peptide antibody indices in the diagnosis of rheumatoid arthritis and ankylosing spondylitis.
    Rashid T, Ebringer A, Wilson C, Bansal S, Paimela L, Binder A.
    J Clin Rheumatol; 2006 Feb 19; 12(1):11-6. PubMed ID: 16484874
    [Abstract] [Full Text] [Related]

  • 17. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation.
    Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P.
    J Rheumatol; 2002 Jul 19; 29(7):1430-6. PubMed ID: 12136902
    [Abstract] [Full Text] [Related]

  • 18. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 19; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 19. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
    Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U.
    Eur J Haematol; 2008 Jun 19; 80(6):490-4. PubMed ID: 18331598
    [Abstract] [Full Text] [Related]

  • 20. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN.
    Arthritis Rheum; 1998 Jul 19; 41(7):1258-65. PubMed ID: 9663484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.